^
    9h
    CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect. (PubMed, Cancer Immunol Immunother)
    Additionally, treatment with revumenib, a menin inhibitor, increased CLL-1 expression in AML cells harboring mixed-lineage leukemia (MLL) fusion genes or the NPM1 mutation, making them more susceptible to 2-23 CAR T cell-mediated cytotoxicity in vitro. These findings suggest that the clinical efficacy of CAR T cells derived from the novel, high-affinity anti-CLL-1 mAb 2-23 should be tested in patients with CLL-1-positive AML and also that combining 2-23 CAR T cells with revumenib may benefit some patients with CLL-1low/- AML.
    Journal
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    |
    Revuforj (revumenib)
    9h
    Single Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. (PubMed, Mol Genet Genomic Med)
    This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP-ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • EBF1 (EBF Transcription Factor 1)
    9h
    Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial primary completion date
    10h
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV
    10h
    A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    12h
    Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib)
    13h
    Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV
    13h
    Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    14h
    Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker (clinicaltrials.gov)
    P2, N=112, Not yet recruiting, The Methodist Hospital Research Institute | Initiation date: Jul 2025 --> Apr 2026
    Trial initiation date • IO biomarker • Minimal residual disease
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • decitabine
    14h
    Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (clinicaltrials.gov)
    P=N/A, N=10, Completed, Massachusetts General Hospital | Recruiting --> Completed | Trial completion date: Jul 2027 --> Jul 2025
    Trial completion • Trial completion date
    15h
    Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax)
    16h
    Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • Xpovio (selinexor) • daunorubicin • Starasid (cytarabine ocfosfate)